Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 193 #1
CompanyRegulus Therapeutics Inc.
Market Cap596.61MEPS (ttm)-0.67
P/E-EPS this Y76.90%
Forward P/E-EPS next Y27.70%
PEG-EPS past 5Y0.00%
P/S42.92EPS next 5Y-
P/B7.28EPS Q/Q-40.00%
Dividend-Sales Q/Q-85.40%
Insider Own0.20%Inst Own33.10%
Insider Trans-70.86%Inst Trans-0.02%
Short Float11.86%EarningsNov 11/a
Analyst Recom1.70Target Price16.40
Avg Volume64.23K52W Range5.40 - 11.88
22-Oct-14 08:48AMREGULUS THERAPEUTICS INC. Files SEC form 8-K, Termination of a Material Definitive Agreement EDGAR Online
22-Oct-14 08:30AMRegulus Therapeutics Inc. RG-101 Human Proof of Concept Call scheduled for 8:30 am ET today CCBN
22-Oct-14 07:32AM7:32 am Regulus Therapeutics announced that it has demonstrated human proof-of-concept with a microRNA therapeutic from an ongoing clinical study evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting microRNA-122, for the Briefing.com
22-Oct-14 07:30AMA Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Tr PR Newswire
14-Oct-14 08:00AMRegulus Presents New Preclinical Data on Multiple Programs and Provides Portfolio Overview at 10th Annual Oligonucleotide Therapeutics Society (OTS) Meeting PR Newswire
24-Sep-14 08:00AMRegulus Announces Notice of Allowance from U.S. Patent Office Related to microRNA-103/107 Program in Metabolic Disorders PR Newswire
19-Sep-14 05:06PMREGULUS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh EDGAR Online
19-Sep-14 07:52AMWedbush Securities Reacts To Regulus Therapeutics Inc Announcing ATHENA Natural History Study Benzinga
18-Sep-14 08:00AMRegulus Initiates ATHENA Natural History of Disease Study in Alport Syndrome Patients PR Newswire
04-Sep-14 09:13PM5 Breakout Stocks Under $10 Set to Soar at TheStreet
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. The company uses its microRNA product platform to develop anti-miRs, which is chemically modified and single-stranded oligonucleotide. Its clinical candidate products include RG-101, which is a GalNAc-conjugated anti-miR that targets microRNA-122 for the treatment of patients with chronic hepatitis C virus infection. The company has strategic collaboration with Biogen Idec MA Inc. for the evaluation of the use of microRNA signatures as a biomarker for human patients with multiple sclerosis; AstraZeneca AB to discover and develop microRNA therapeutics for cardiovascular diseases, metabolic diseases, and oncology; and GlaxoSmithKline plc to discover and develop microRNA therapeutics for immuno-inflammatory diseases. It also has strategic collaboration with Sanofi for the discovery and development of microRNA therapeutics comprising miR-21 pre-clinical fibrosis program for the treatment of alport syndrome and preclinical program for oncology indications; and preclinical programs targeting miR-221/222 for oncology indications. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
XANTHOPOULOS KLEANTHIS GPresident and CEOOct 20Option Exercise0.383001142,766Oct 21 04:07 PM
XANTHOPOULOS KLEANTHIS GPresident and CEOOct 20Sale7.003002,1002,466Oct 21 04:07 PM
XANTHOPOULOS KLEANTHIS GPresident and CEOOct 17Option Exercise0.384001522,866Oct 21 04:07 PM
XANTHOPOULOS KLEANTHIS GPresident and CEOOct 17Sale7.044002,8162,466Oct 21 04:07 PM
ISIS PHARMACEUTICALS INCDirectorOct 17Sale6.793,00020,3716,908,800Oct 17 05:38 PM
CompanyAkorn, Inc.
IndustryDrugs - Generic
Market Cap4.34BEPS (ttm)0.41
P/E101.73EPS this Y43.80%
Forward P/E26.17EPS next Y55.36%
PEG4.08EPS past 5Y48.00%
P/S10.64EPS next 5Y24.93%
P/B14.64EPS Q/Q-27.30%
Dividend-Sales Q/Q95.70%
Insider Own2.60%Inst Own83.90%
Insider Trans187.90%Inst Trans0.24%
Short Float13.75%EarningsNov 03/b
Analyst Recom1.90Target Price40.60
Avg Volume1.20M52W Range20.08 - 41.40
22-Oct-14 07:22AMAkorn (AKRX) Looks Good: Stock Adds 5.8% in Session Zacks
21-Oct-14 04:24PMStocks Extend Comeback; S&P 500 Retakes 200-Day Line at Investor's Business Daily
21-Oct-14 12:03PMStocks Extend Gains At Midday; Akorn Clears Buy Point at Investor's Business Daily
21-Oct-14 11:02AMAkorn, Inc. Announces Third Quarter 2014 Earnings Release and Conference Call Information GlobeNewswire
21-Oct-14 10:38AMStocks Post Solid Early Advance; Apple Lifts Nasdaq, S&P 500 at Investor's Business Daily
21-Oct-14 09:45AMNew Lifetime High For Akorn (AKRX) at TheStreet
21-Oct-14 08:02AMFacebook, Keurig Among 5 Top Stocks For Any Economy at Investor's Business Daily
20-Oct-14 06:01PMAlexion: Keeping Up The Suspense Ahead Of Q3 Earnings at Investor's Business Daily
20-Oct-14 01:21PMNasdaq Extends Gains; Apple, Chipotle Rise Pre-Earnings at Investor's Business Daily
20-Oct-14 10:05AMTrade-Ideas: Akorn (AKRX) Is Today's Strong On High Relative Volume Stock at TheStreet
Akorn, Inc. manufactures and markets diagnostic and therapeutic ophthalmic pharmaceuticals, niche hospital drugs, and injectable pharmaceuticals in the United States and internationally. It offers products in various areas, including ophthalmology, antidotes, anti-infectives, pain management, anesthesia, vaccines, and others. The company operates in three segments: Ophthalmic, Hospital Drugs & Injectables, and Contract Services. The Ophthalmic segment markets diagnostic products, such as mydriatics and cycloplegics, anesthetics, topical stains, gonioscopic solutions, angiography dyes, and others for use in the office setting; therapeutic products, including antibiotics, steroids, steroid combinations, glaucoma medications, decongestants/antihistamines, and anti-edema medications to wholesalers, chain drug stores, and other national account customers; non-pharmaceutical products comprising artificial tear solutions, preservative-free lubricating ointments, and eyelid cleansers; and over-the-counter dry eye and other eye health products under the TheraTears name through chain drug stores and big box retailers, as well as directly to optometrists, ophthalmologists, and other eye care practitioners and clinics. This segment offers ophthalmic products, such as AzaSite, an azithromycin ophthalmic solution; Cosopt, a dorzolamide hydrochloride and timolol maleate ophthalmic solution; and Cosopt PF, a preservative-free prescription version of Cosopt. The Hospital Drugs & Injectables segment provides hospital drug and injectable pharmaceutical products comprising antidotes, anti-infectives, controlled substances for pain management and anesthesia, and other pharmaceutical products to hospitals through the wholesale distribution channel. The Contract Services segment manufactures various pharmaceutical products for third party pharmaceutical customers based on their specifications. The company was founded in 1971 and is headquartered in Lake Forest, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Silverberg Mark MExec VP, Ops Global QA&TechSrvOct 21Option Exercise1.48210,000311,500279,911Oct 22 08:02 PM
Silverberg Mark MExec VP, Ops Global QA&TechSrvOct 21Sale40.0072,4912,899,640207,420Oct 22 08:02 PM
MEYER STEVEN JDirectorOct 13Option Exercise2.6115,00039,15073,556Oct 14 07:26 PM
Dick Timothy AChief Financial OfficerOct 01Option Exercise2.04122,222248,722245,210Oct 03 05:12 PM
Dick Timothy AChief Financial OfficerOct 01Sale35.24122,2224,307,103122,988Oct 03 05:12 PM
CompanyCovenant Transportation Group, Inc.
Market Cap310.12MEPS (ttm)0.51
P/E40.65EPS this Y-14.60%
Forward P/E17.45EPS next Y41.77%
PEG8.13EPS past 5Y15.90%
P/S0.45EPS next 5Y5.00%
P/B3.00EPS Q/Q92.30%
Dividend-Sales Q/Q0.70%
Insider Own31.90%Inst Own54.50%
Insider Trans1.32%Inst Trans0.53%
Short Float0.73%EarningsOct 15/a
Analyst Recom1.50Target Price19.33
Avg Volume112.20K52W Range6.16 - 19.30
22-Oct-14 09:44AMCOVENANT TRANSPORTATION GROUP INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statem EDGAR Online
21-Oct-14 04:00PMCovenant Transportation Group Announces Third Quarter Financial and Operating Results GlobeNewswire
15-Oct-14 03:56PMCovenant Transportation Group, Inc. Announces Timing of Third Quarter Earnings Release and Conference Call GlobeNewswire
10-Oct-14 06:39AMWhy You Shouldn't Bet Against Covenant Transportation Group (CVTI) Stock Zacks
08-Oct-14 09:30AMBull of the Day: Covenant Transportation (CVTI) Zacks
07-Oct-14 10:24AMCovenant Transportation (CVTI) Shares March Higher, Can It Continue? Zacks
29-Sep-14 08:08AMThe Zacks Analyst Blog Highlights: Con-way, Covenant Transportation Group, Old Dominion Freight Line, MannKind and Sanofi Zacks
26-Sep-14 07:57AMSwift Transportation (SWFT) in Focus: Stock Moves 9.6% Higher Zacks
25-Sep-14 06:39AMIncreased Earnings Estimates Seen for Covenant Transportation Group (CVTI): Can It Move Higher? Zacks
16-Sep-14 10:37AMCan the Uptrend Continue for Covenant Transportation (CVTI)? Zacks
Covenant Transportation Group, Inc., together with its subsidiaries, offers truckload transportation and brokerage services in the continental United States. Its Asset-Based Truckload Services segment provides long haul, dedicated, temperature-controlled, and regional solo-driver services. The company also offers freight brokerage services directly, as well as through freight brokerage agents; less-than-truckload consolidation services; and accounts receivable factoring services. It serves transportation companies, such as freight forwarders, less-than-truckload carriers, and third-party logistics providers, as well as traditional truckload customers, including manufacturers, retailers, and food and beverage shippers. As of December 31, 2013, the company operated 2,688 tractors and 6,861 trailers. Covenant Transportation Group, Inc. was founded in 1994 and is headquartered in Chattanooga, Tennessee.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hough Samuel FExec VP & COO of SubsidiarySep 04Buy12.961,00012,96036,624Sep 09 04:40 PM
LOVIN RALPH H JRExecutive VP and SecretaryAug 22Sale13.531,32617,94185,089Aug 25 03:53 PM
LOVIN RALPH H JRExecutive VP and SecretaryMar 06Sale11.551,40916,27590,442Mar 06 05:42 PM
LOVIN RALPH H JRExecutive VP and SecretaryMar 03Sale10.052,65026,63393,349Mar 04 06:07 PM
TickerKNX [NYSE]
CompanyKnight Transportation Inc.
Market Cap2.25BEPS (ttm)0.99
P/E28.03EPS this Y7.50%
Forward P/E20.76EPS next Y18.42%
PEG1.69EPS past 5Y5.40%
P/S2.24EPS next 5Y16.63%
P/B3.70EPS Q/Q33.30%
Dividend0.86%Sales Q/Q7.90%
Insider Own0.20%Inst Own84.90%
Insider Trans-6.36%Inst Trans-0.29%
Short Float9.22%EarningsOct 22/b
Analyst Recom2.50Target Price29.60
Avg Volume588.99K52W Range16.50 - 28.92
22-Oct-14 09:04AM9:04 am Knight Transportation beats by $0.04, beats on revs Briefing.com
22-Oct-14 09:03AMKnight Transportation tops Street 3Q forecasts AP
22-Oct-14 09:00AMKnight Transportation Reports Third Quarter 2014 Revenue and Earnings Business Wire
22-Oct-14 07:07AMQ3 2014 Knight Transportation Inc Earnings Release - Before Market Open CCBN
21-Oct-14 07:10AMShould You Buy Knight Transportation (CHFC) Ahead of Earnings? Zacks
15-Oct-14 09:35AMZacks Industry Rank Analysis Highlights: Fed Ex, Kansas City Southern, Kirby, Knight Transportation and SAIA Zacks
15-Oct-14 07:04AMIs Knight Transportation (KNX) Stock a Solid Choice Right Now? Zacks
08-Oct-14 09:00AMKnight Transportation, Inc. Announces Upcoming Release of Third Quarter Earnings and Related Conference Call Business Wire
02-Oct-14 05:22PMToday's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
01-Oct-14 09:31AMKNIGHT TRANSPORTATION INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition o EDGAR Online
Knight Transportation, Inc., together with its subsidiaries, operates as a short to medium-haul truckload carrier of general commodities primarily in the United States. The company operates in two segments, Asset-Based and Non-Asset-Based. The Asset-Based segment provides truckload carrier dry van; temperature-controlled (refrigerated); dedicated truckload; and drayage services between ocean ports, rail ramps, and shipping docks. The Non-Asset-Based segment provides logistics, freight management, freight brokerage, rail intermodal, and other non-trucking services. As of December 31, 2013, it operated 3,537 company-owned tractors, as well as had 452 tractors under contract that are owned and operated by independent contractors, as well as operated an average of 9,406 trailers. Knight Transportation, Inc. was founded in 1989 and is headquartered in Phoenix, Arizona.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KNIGHT TRANSPORTATION INC10% OwnerAug 04Sale18.1217,000308,0401,051,117Aug 04 04:08 PM
KNIGHT TRANSPORTATION INC10% OwnerAug 01Sale18.0330,700553,5211,068,117Aug 04 04:08 PM
KNIGHT TRANSPORTATION INC10% OwnerJul 31Sale18.5594,3001,749,2651,098,817Aug 04 04:08 PM
KNIGHT KEITH TChief Operating OfficerJun 10Option Exercise12.5722,500282,9025,247,513Jun 11 06:06 PM
KNIGHT KEITH TChief Operating OfficerJun 10Sale24.2522,500545,5805,225,013Jun 11 06:06 PM
CompanyRadNet, Inc.
IndustryMedical Laboratories & Research
Market Cap378.14MEPS (ttm)-0.17
P/E-EPS this Y-96.70%
Forward P/E16.72EPS next Y112.00%
PEG-EPS past 5Y16.40%
P/S0.54EPS next 5Y10.00%
P/B-EPS Q/Q71.40%
Dividend-Sales Q/Q1.50%
Insider Own7.60%Inst Own41.90%
Insider Trans6.85%Inst Trans0.48%
Short Float5.81%EarningsNov 10/b
Analyst Recom2.30Target Price8.50
Avg Volume480.67K52W Range1.50 - 8.84
17-Oct-14 10:00AMRadNet (RDNT) Flagged As Strong On High Volume at TheStreet
16-Oct-14 07:22AMCan the Rally in RadNet (RDNT) Shares Continue? Zacks
09-Oct-14 11:47AMDavid Stoller, MD, to Host Upcoming CME Course in Orthopaedic Imaging GlobeNewswire
16-Sep-14 09:32AMMadison Radiology Medical Group Implements eRAD RIS GlobeNewswire
12-Sep-14 07:47AMStrength Seen in RadNet (RDNT): Stock Gains 11.2% Zacks
09-Sep-14 09:39AMAMIC Chicago Implements eRAD PACS Cloud Solution GlobeNewswire
19-Aug-14 01:04PMRADNET, INC. Financials EDGAR Online Financials
14-Aug-14 11:15AMRadNet Inc Stock Upgraded (RDNT) at TheStreet
11-Aug-14 07:30AMStrength Seen in RadNet (RDNT): Stock Soars 20.8% Zacks
11-Aug-14 06:00AMRADNET, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
RadNet, Inc. provides outpatient diagnostic imaging services in the United States. The company offers various imaging services, including magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy, and other related procedures. It also provides teleradiology services for remote interpretation of images on behalf of radiology groups, hospitals, and imaging center customers. In addition, the company develops and sells computerized systems for the imaging industry, including picture archiving communications and radiology information systems, and related workflow solutions for hospitals, teleradiology businesses, imaging centers, and specialty physician groups to distribute, visualize, store, and retrieve digital images taken from various diagnostic imaging modalities. As of April 9, 2014, it operated a network of 250 owned and/or operated outpatient imaging centers primarily in California, Maryland, Delaware, New Jersey, New York, and Rhode Island. The company was founded in 1985 and is headquartered in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CRUES JOHN VMedical DirectorAug 18Sale6.9116,667115,169768,112Aug 18 05:16 PM
SHERMAN MICHAEL L MDDirectorJun 05Sale6.6726,752178,335214,065Jun 06 12:54 PM
STOLPER MARKExecutive VP and CFOMay 13Sale6.4775,000485,250266,387May 13 05:25 PM
CRUES JOHN VMedical DirectorMay 13Sale6.4016,667106,669784,779May 13 05:24 PM
SHERMAN MICHAEL L MDDirectorMar 31Option Exercise2.4031,25075,000267,225Apr 01 01:07 PM
TickerAAC [NYSE]
CompanyAAC Holdings, Inc.
IndustrySpecialized Health Services
Market Cap424.15MEPS (ttm)0.03
P/E684.00EPS this Y28.60%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S3.67EPS next 5Y-
P/B16.03EPS Q/Q-86.70%
Dividend-Sales Q/Q-1.00%
Insider Own43.30%Inst Own-
Insider Trans-3.64%Inst Trans-
Short Float0.01%Earnings-
Analyst Recom-Target Price-
Avg Volume289.01K52W Range17.60 - 20.10
07-Oct-14 04:01PMAAC Holdings, Inc. Announces Closing of Initial Public Offering Business Wire
02-Oct-14 04:02PMOnline Retailer Wayfair Leads List Of 6 IPOs Thursday at Investor's Business Daily
01-Oct-14 07:04PMAAC Holdings, Inc. Announces Pricing of Initial Public Offering Business Wire
AAC Holdings, Inc. provides substance abuse treatment services. It offers treatment services for behavioral health disorders. The company also provides detoxification, residential treatment, partial hospitalization, and intensive outpatient care services. AAC Holdings, Inc. was incorporated in 2014 and is headquartered in Brentwood, Tennessee.
TickerAUO [NYSE]
CompanyAU Optronics Corp.
IndustrySemiconductor - Broad Line
Market Cap4.00BEPS (ttm)0.25
P/E16.64EPS this Y106.40%
Forward P/E14.86EPS next Y-22.87%
PEG0.48EPS past 5Y-23.30%
P/S0.30EPS next 5Y34.80%
P/B0.73EPS Q/Q0.00%
Dividend-Sales Q/Q-9.20%
Insider Own-Inst Own5.20%
Insider Trans-Inst Trans0.64%
Short Float0.77%EarningsJan 27
Analyst Recom3.00Target Price4.51
Avg Volume900.60K52W Range3.90 - 4.03
20-Oct-14 07:55AMFabrinet (FN) in Focus: Stock Adds 8.5% in Session Zacks
17-Oct-14 01:23AMLG Display: Weak Golden Week, Credit Suisse Downgrades at Barrons.com
14-Oct-14 08:01AMZacks Rank #1 Additions for Tuesday Zacks
10-Oct-14 12:50PMTE Connectivity Buys Measurement Specialities for $1.7B Zacks
10-Oct-14 06:41AMWhat Falling Estimates & Price Mean for Park Electrochemical (PKE) Zacks
09-Oct-14 08:13AMZacks Rank #1 Additions for Thursday Zacks
08-Sep-14 02:47AMWhy LG Display Is JP Morgan's Favorite Apple Supplier at Barrons.com
31-Aug-14 12:00AMUsing Mean Reversion and Momentum for Possible Advantage Yahoo Finance Blogs
26-Aug-14 02:51AMAUO's Next Generation UHD 4K Wide Color Gamut Curved LCD TV Displays Make Stunning Presence PR Newswire
25-Aug-14 05:10AMAUO's High Resolution a-Si TFT-LCDs for Mobile Devices Make First Appearance at Touch Taiwan 2014 PR Newswire
AU Optronics Corp. is engaged in the design, development, production, assembly, and marketing of thin film transistor liquid crystal displays and other flat panel displays. The company operates in two segments, Display and Solar. The Display segment offers a range of display panels for use in mobile PCs, such as notebooks and tablets; desktop monitors; consumer electronics products consisting of mobile phones, digital still cameras, portable navigation displays, digital camcorders, automobile displays, amusement and printer displays, and portable gaming consoles; and LCD televisions. This segment sells its panels to original equipment manufacturing service providers who manufacture products on a contract basis for brand companies; and to brand companies on a direct shipment basis. The Solar segment manufactures upstream and midstream products, such as polysilicons, ingots, wafers, and solar cells; designs, develops, and manufactures solar photovoltaic (PV) modules; produces solar PV systems; and provides various value-added services for solar PV systems projects. The company operates in Taiwan, the People's Republic of China, Japan, Singapore, the United States, Korea, and internationally. AU Optronics Corp. was founded in 1996 and is based in Hsinchu, Taiwan.
CompanyFederated National Holding Company
IndustryProperty & Casualty Insurance
Market Cap438.74MEPS (ttm)2.59
P/E12.27EPS this Y168.50%
Forward P/E14.15EPS next Y-8.18%
PEG0.61EPS past 5Y46.20%
P/S2.43EPS next 5Y20.00%
P/B2.70EPS Q/Q225.80%
Dividend0.38%Sales Q/Q109.20%
Insider Own7.30%Inst Own41.50%
Insider Trans17.89%Inst Trans1.11%
Short Float4.68%EarningsOct 31/a
Analyst Recom2.30Target Price24.50
Avg Volume245.38K52W Range9.91 - 32.47
16-Oct-14 02:00PMFederated National Holding Company Announces Financial Results Release Date GlobeNewswire
09-Oct-14 02:45PMFederated National Hits 52-Week High on Positive Tidings Zacks
07-Oct-14 07:04AMWhy Federated National (FNHC) Isn't Done Growing Earnings Yet Zacks
07-Oct-14 07:00AMCan Federated National Holding (FNHC) Keep the Earnings Streak Alive This Quarter? Zacks
03-Oct-14 08:36AMWill Federated National (FNHC) Continue to Surge Higher? Zacks
25-Sep-14 06:48AMWhy You Shouldn't Bet Against Federated National Holding Stock Zacks
18-Sep-14 03:10PMShould Agro Group (AGII) Stock Be in Your Portfolio Now? Zacks
17-Sep-14 01:40PMAmerican Financial Issues $150M Subordinated Debentures Zacks
12-Sep-14 12:30PMCincinnati Financial Benefits from Disciplined Underwriting Zacks
10-Sep-14 02:00PMFederated National Holding Company Declares Regular Quarterly Dividend GlobeNewswire
Federated National Holding Company, through its subsidiaries, is engaged in the insurance underwriting, distribution, and claims processing in the United States. It underwrites homeowners' multi-peril, commercial general liability, federal flood, workers compensation, personal umbrella, inland marine, fire, allied lines, personal and commercial automobile, and other lines of insurance. Federated National Holding Company markets and distributes its own and third-party insurers' products and other services through contractual relationships with independent agents and general agents. The company was formerly known as 21st Century Holding Company and changed its name to Federated National Holding Company in September 2012. Federated National Holding Company was founded in 1991 and is based in Sunrise, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WILCOX RICHARD W JRDirectorSep 30Option Exercise2.453,3338,166132,392Oct 02 07:22 PM
Braun Michael HChief Executive Officer & PresSep 11Option Exercise4.7340,500191,495281,544Sep 11 06:17 PM
Braun Michael HChief Executive Officer & PresSep 11Sale25.0027,336683,340254,178Sep 11 06:17 PM
PRYGELSKI PETER JChief Financial Officer & TreaAug 06Sale20.953,00062,86583,000Aug 07 04:18 PM
SIMBERG BRUCEChairman of the BoardAug 01Buy19.5010,000195,000452,032Aug 06 04:25 PM
CompanyAgios Pharmaceuticals, Inc.
Market Cap2.54BEPS (ttm)-2.06
P/E-EPS this Y64.70%
Forward P/E-EPS next Y22.70%
PEG-EPS past 5Y0.00%
P/S85.36EPS next 5Y-
P/B12.37EPS Q/Q80.70%
Dividend-Sales Q/Q33.30%
Insider Own15.30%Inst Own83.50%
Insider Trans-58.66%Inst Trans3.75%
Short Float11.90%EarningsNov 03
Analyst Recom1.60Target Price70.75
Avg Volume549.90K52W Range15.77 - 73.99
21-Oct-14 01:44PMMidday Gainers From October 21: Aircastle, American Airlines, Agios Pharmaceuticals Benzinga
21-Oct-14 08:30AMAgios Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of AG-221 in Patients with Advanced Solid Tumors with an IDH2 Mutation GlobeNewswire
16-Oct-14 03:15PMAgios (AGIO) Rises on Expansion of Phase I Study on AG-221 Zacks
15-Oct-14 05:49PMToday's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
15-Oct-14 08:30AMAGIOS PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
15-Oct-14 07:30AMAgios Pharmaceuticals Announces Initiation of Four Expansion Cohorts in Phase 1 Study of AG-221 GlobeNewswire
06-Oct-14 10:06AMInsider Trading Alert - AGIO, ACN And CTAS Traded By Insiders at TheStreet
06-Oct-14 09:00AMAgios Pharmaceuticals to Webcast R&D Day on October 15, 2014 GlobeNewswire
29-Sep-14 04:30PMAgios to Present Data on AG-120 in November, Shares Rises Zacks
29-Sep-14 12:07PMFive Reasons Celgene Could Gain 20% at Barrons.com
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its product candidates include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. The company is also developing AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation to discover, develop, and commercialize disease-altering therapies in oncology. Agios Pharmaceuticals, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Biller ScottChief Scientific OfficerOct 01Option Exercise0.474,5002,10439,500Oct 03 05:04 PM
Schenkein David PChief Executive OfficerOct 01Option Exercise0.302,500756255,772Oct 03 05:06 PM
Biller ScottChief Scientific OfficerOct 01Sale60.074,500270,31535,000Oct 03 05:04 PM
Higgons John DuncanChief Operating OfficerOct 01Sale60.0713,000780,910156,835Oct 03 05:05 PM
Schenkein David PChief Executive OfficerOct 01Sale60.0713,000780,910131,272Oct 03 05:06 PM
CompanySonic Corp.
Market Cap1.33BEPS (ttm)0.73
P/E33.59EPS this Y6.70%
Forward P/E24.79EPS next Y18.73%
PEG2.08EPS past 5Y-8.00%
P/S2.42EPS next 5Y16.12%
P/B23.13EPS Q/Q15.40%
Dividend1.47%Sales Q/Q3.80%
Insider Own3.10%Inst Own99.80%
Insider Trans-9.65%Inst Trans-1.99%
Short Float10.23%EarningsOct 21/a
Analyst Recom2.50Target Price23.29
Avg Volume651.43K52W Range16.62 - 24.01
22-Oct-14Reiterated Wunderlich Buy $26 → $28
22-Oct-14Reiterated Telsey Advisory Group Underperform $19 → $23
22-Oct-14Reiterated Oppenheimer Outperform $25 → $27
22-Oct-14 07:25AMSonic Earnings And Sales Please Investors Benzinga
21-Oct-14 04:48PMSonic beats Street 4Q forecasts AP
21-Oct-14 04:27PMSONIC CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
21-Oct-14 04:07PM4:07 pm Sonic reports EPS in-line, beats on revs; guides FY15 EPS in-line Briefing.com
21-Oct-14 04:01PMSonic Announces 4.6% System Same-Store Sales Increase for Fourth Fiscal Quarter Business Wire
21-Oct-14 07:07AMQ4 2014 SONIC CORP Earnings Release - After Market Close CCBN
17-Oct-14 06:39AMShould You Buy Sonic (SONC) Ahead of Earnings? Zacks
08-Oct-14 09:42AMThe mom behind Target's gun ban at CNNMoney.com
02-Oct-14 10:35AMGuns welcome at these restaurants at CNNMoney.com
30-Sep-14 10:14AMNot Your Ordinary Wings, Not Your Ordinary Sauces Business Wire
Sonic Corp. operates and franchises a chain of quick-service drive-in restaurants in the United States. As of January 07, 2014, it operated approximately 3,500 drive-in restaurants in 44 states. It also leases signs and real estate. The company was founded in 1953 and is headquartered in Oklahoma City, Oklahoma.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROSENBERG ROBERT MDirectorSep 04Sale21.5620,000431,20068,397Sep 05 04:28 PM
RICHARDSON FRANK E IIIDirectorAug 18Sale22.0723,550519,7461,541,145Aug 19 04:35 PM
SCHUTZ JEFFREY HDirectorAug 07Option Exercise0.001,357029,416Aug 08 04:50 PM
RICHARDSON FRANK E IIIDirectorJul 30Sale21.503006,4501,564,695Jul 30 05:04 PM
RICHARDSON FRANK E IIIDirectorJul 28Sale21.501,15024,7281,564,995Jul 30 05:04 PM
1 2 3 4 5 6 ... 10 ... 20 next